Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Background: We aim to understand whether all patients with hormonal receptor (HR)-positive (+)/human epidermal growth factor receptor-2 (HER2)-negative (−) metastatic breast cancer (MBC) should receive cyclin D-dependent kinase (CDK) 4/6 inhibitor-based therapy as a first-line approach. Methods: A network meta-analysis (NMA) using the Bayesian hierarchical arm-based model, which provides the estimates for various effect sizes, were computed. Results: First-line treatment options in HR+/HER2− MBC, including CDK 4/6 inhibitors combined with aromatase inhibitors (AIs) or fulvestrant (F), showed a significantly longer progression-free survival (PFS) in comparison with AI monotherapy, with a total of 26% progression risk reduction. In the indirect comparison across the three classes of CDK 4/6 inhibitors and F endocrine-based therapies, the first strategy resulted in longer PFS, regardless of specific CDK 4/6 inhibitor (HR: 0.68; 95% CrI: 0.53–0.87 for palbociclib + AI, HR: 0.65; 95% CrI: 0.53–0.79 for ribociclib + AI, HR: 0.63; 95% CrI: 0.47–0.86 for abemaciclib + AI) and patient’s characteristics. Longer PFS was also found in patients with bone-only and soft tissues limited disease treated with CDK 4/6 inhibitors. Conclusions: CDK 4/6 inhibitors have similar efficacy when associated with an AI in the first-line treatment of HR+ MBC, and are superior to either F or AI monotherapy, regardless of any other patients or tumor characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In recent years, a number of agents that improve patient outcomes have been approved by regulatory agencies in this setting, including those targeting the mammalian target of rapamycin, phosphatidylinositide 3-kinase, and cyclin-dependent kinase (CDK) pathways.3-5”
From E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group (2021) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938 · cited 2×
“Hormone receptor (HR)-positive (+) and human epidermal growth factor receptor type (HER2)-negative (−) metastatic breast cancer (MBC) represents the most common invasive cancer subtype in women [1].”
BackgroundPalbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · cited 5×
“PALOMA-2 Finn [12] 2016 III First-line therapy for MBC in patients not treated before for their metastatic disease.”
BackgroundMethodInfluentialAlpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622 · cited 2×
“explored the safety and efficacy of only two CDK 4/6 inhibitors (palbociclib and ribociclib) in postmenopausal women after progression on a non-steroidal AI [35].”
BackgroundCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827 · cited 1×
“In particular, palbociclib, ribociclib, and abemaciclib, the three available CDK 4/6 inhibitors, in combination with standard ET, showed progression-free survival (PFS) improvement in phase III trials, and have been approved for use in first and in later lines of therapy in women with HR+HER2− MBC, regardless of menop…”
BackgroundMONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., Chen, S.-C., Manso, L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.6155 · Cited by 1,744
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276 · cited 1×
“9) in the ET alone arm [18,19] In addition, also the SWOG trial has recently shown the median OS of 49.”
BackgroundTripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025 · cited 4×
“ro g the search strategy, we identified four phase III trials comparing 1441 patients treated with CDK 4/6 inhibitors (palbociclib, ribociclibor, abemaciclib) in combination with an AI (1106 patients) [12–14], an AI plus ovarian fu ction suppression (OFS; 248 premenopausal patients), or tamoxifen plus OFS (87 premenop…”
MethodInfluentialOverall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001
Overview of resistance to systemic therapy in patients with breast cancer
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904 · cited 1×
“Almost two-thirds of women with newly diagnosed MBC have HR+ tumors, and approximately 25% of women with an early HR+ breast cancer diagnosis eventually relapse after adjuvant treatments [2].”
BackgroundHortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy155 · Cited by 876 · cited 4×
“PALOMA-2 Palbociclib–letrozole Any AEs 62.2% 13.5% Neutropenia 56.1% 10.4% Leukopenia 24.1% 0.7% Placebo–letrozole Any AEs 22.1% 2.3% Neutropenia 0.9% 0.5% MONALEESA-2 Ribociclib–letrozole Neutropenia 52.4% 9.6% Abnormal LFT 8.4% 1.8% Leukopenia 20.1% 1.2% Placebo–letrozole Abnormal LFT 2.4% – Neutropenia, anemia, art…”
BackgroundMethodInfluential
Cited by
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
Wang, X., Zhao, S., Xin, Q., Zhang, Y., Wang, K., & Li, M. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00747-x · Cited by 163
“The fi ndings indicated a signi fi cant enhancement in both PFS and ORR when CDK4/6i were administered to patients with BM [55].”
MethodResistance and Overcoming Resistance in Breast Cancer
Luque-Bolivar, A., Pérez-Mora, E., Villegas, V. E., & Rondón‐Lagos, M. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s270799 · Cited by 163
Connolly, R. M., Zhao, F., Miller, K. D., Lee, M.-J., Piekarz, R. L., Smith, K. L., Brown-Glaberman, U. A., Winn, J. S., Faller, B. A., Onitilo, A. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00944 · Cited by 125
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib
Chong, Q.-Y., Kok, Z. H., Bui, N.-L.-C., Xiang, X., Wong, A. L., Yong, W. P., Sethi, G., Lobie, P. E., Wang, L., & Goh, B.-C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104686 · Cited by 115
Roberto, M., Astone, A., Botticelli, A., Carbognin, L., Cassano, A., D’Auria, G., Fabbri, A., Fabi, A., Gamucci, T., Krasniqi, E., et al. (2021) · Cancers · doi:10.3390/cancers13020332 · Cited by 71
“A network meta-analysis, including patients treated with CDK4/6 inhibitors combined with aromatase inhibitors (AIs) or fulvestrant in comparison with AI or fulvestrant monotherapy, confirmed CDK4/6 inhibitors had similar efficacy when associated with an AI in the first-line treatment of HR+ ABC, and were superior to e…”
ResultSelf-citation
Metadata
- Authors
- Rossi, V., Berchialla, P., Giannarelli, D., Nisticò, C., Ferretti, G., Gasparro, S., Russillo, M., Catania, G., Vigna, L., Mancusi, R. L., Bria, E., Montemurro, F., Cognetti, F., & Fabi, A.
- Affiliations
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- University of Turin (IT)
- Instituto Nazionale Tumori Regina Elena (IT)
- University of Rome Tor Vergata (IT)
- Università Cattolica del Sacro Cuore (IT)
- Candiolo Cancer Institute (IT)
- Sapienza University of Rome (IT)
- Corresponding author
- Fabi, Alessandra
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-10-26
- Volume
- 11
- Issue
- 11
- Pages
- 1661
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC6896062
- OpenAlex
- W2981795130
- Cited by
- 70
- References
- 37
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 12 · 2021: 23 · 2020: 7
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Pfizer
- Celgene
- Helsinn
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- HR-positive HER2-negative metastatic breast cancer, CDK4/6 inhibitors, first-line therapy, aromatase inhibitors, fulvestrant, palbociclib, ribociclib, abemaciclib, progression-free survival, endocrine therapy, soft tissue disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. https://app.cochat.ai/papers/10.3390/cancers11111661
- The paper
- Rossi, V., Berchialla, P., Giannarelli, D., Nisticò, C., Ferretti, G., Gasparro, S., Russillo, M., Catania, G., Vigna, L., Mancusi, R. L., Bria, E., Montemurro, F., Cognetti, F., & Fabi, A. (2019). Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. Cancers. https://doi.org/10.3390/cancers11111661
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.